Evidence map›Paper›PMID 23223596›Full record

SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013

Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Rositsa B Dimova, Marija Zeremski, Ira M Jacobson, Holly Hagan, Don C Des Jarlais, Andrew H Talal

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 6 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 6 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Guideline
  2. KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2016
    Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2014
    Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Rositsa B DimovaWeill Cornell Medical College, New York, NY 10065, USA. rbd2005@med.cornell.edu
Marija Zeremski
Ira M Jacobson
Holly Hagan
Don C Des Jarlais
Andrew H Talal
Cornell University · USMount Sinai Beth Israel · USNew York University · US

Funding

Risk Factors for HIV/AIDS in Drug UsersR01DA003574 · NIDA · NEW YORK UNIVERSITY · PI DES JARLAIS, DON C, MCKNIGHT, COURTNEY · 1986 to 2025
$16.2M
NIDA NIH HHS DA 003574NIDA NIH HHS R01 DA003574
6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV)-infected drug users (DUs) have largely been excluded from HCV care. We conducted a systematic review and meta-analysis of the literature on treatment completion and sustained virologic response (SVR) rates in DUs. We assessed the effects of different treatment approaches and services to promote HCV care among DUs as well as demographic and viral characteristics.

methodsStudies of at least 10 DUs treated with pegylated interferon/ribavirin that reported SVR were analyzed. Heterogeneity was assessed (Cochran test) and investigated (meta-regression), and pooled rates were estimated (random effects).

resultsThirty-six studies comprising 2866 patients were retrieved. The treatment completion rate among DUs was 83.4% (95% confidence interval [CI], 77.1%-88.9%). Among studies that included addiction-treated and untreated patients during HCV therapy, the higher the proportion of addiction-treated patients, the higher the HCV treatment completion rate (P < .0001). After adjusting for human immunodeficiency virus (HIV)/HCV coinfection, sex, and treatment of addiction, support services during antiviral therapy increased treatment completion (P < .0001). The pooled SVR rate was 55.5% (95% CI, 50.6%-60.3%). Genotype 1/4 (P = .0012) and the proportion of HIV-coinfected DUs (P = .0173) influenced the SVR rate. After adjusting for HCV genotype 1/4 and HIV/HCV coinfection, the SVR rate was positively correlated with involvement of a multidisciplinary team (P < .0001).

conclusionsTreatment of addiction during HCV therapy results in higher treatment completion. Our pooled SVR rate is similar to that obtained in registration trials in the general population. Treatment of addiction during HCV therapy will likely be important for HCV-infected DUs undergoing treatment with more complex regimens including direct-acting antivirals.

Indexed as

Medication AdherenceAdultAntiviral AgentsDrug UsersFemaleHepatitis CHumansInterferonsMaleRibavirinSubstance Abuse, IntravenousTreatment OutcomeAntiviral AgentsInterferonsRibavirin

Identifiers

PMID23223596
PMCPMC3582354
OpenAlexW2135630746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.